buy sell hold  

UOB KAYHIAN UOB KAYHIAN

InnoTek (INNOT SP)

Gaining Traction In The EV, Healthcare And Consumer Industries

 

We are confident Innotek can achieve 28% yoy earnings growth for 2021, on the back of robust revenue growth in the auto segment of 45% yoy for 1H21. Also, winning new business in EV, healthcare equipment and gaming consoles should boost growth. Innotek’s solid 1H21 earnings of S$7.2m (+94% yoy) was in line with our expectation, meeting 41% of our full-year estimate. Innotek currently trades at only 5x ex-cash 2022F PE. Maintain BUY and target price of S$1.20 (12x 2022 EPS).

 

Read More ...

   

Banking – Malaysia

Solid 2Q21 Underlying Performance

 

The sector delivered a solid earnings growth of 29% yoy in 1Q21. Pre-provision operating profit growth was also commendable at 7% yoy. Although credit cost is expected to rise hoh in 2H21, we think sector sentiment will remain positive well into 4Q21, supported by economic reopening on high vaccination rates, potential positive dividend surprises and attractive valuations (-1.5SD to mean P/B). Maintain OVERWEIGHT. CIMB is our top sector pick followed by RHB.

 

Read More ...

UOB KAYHIAN

MAYBANK KIM ENG

Gloves – Malaysia

2Q21: Slippery Road To Moderation

 

The 2Q21 reporting season saw slight sequential growth. It also signifies peak quarterly earnings. The road to moderation appears to be swifter than expected. Furthermore, we believe deferred capacity expansion and sub-optimal utilisation rates may not be fully factored in yet. This underlines possible further downside. We believe sentiment could be further weighed by disappointment to consensus expectations. Given the downside risks, we maintain UNDERWEIGHT on the sector.

 

Read More ...

 

 

 

Singapore Market

On to the next phase

 

EPS momentum slowing, but multiples set to expand

Singapore’s easy EPS recovery is slowing. This helped drive one of the strongest YTD market re-ratings regionally. But, we think this is not the end. In past cycles, when earnings upgrades slowed, multiples expanded. Most of the STI sector PEs are below their 5-year mean. Growth markets – Indonesia, Thailand, Vietnam – are continuing to suffer from earnings uncertainty given slow vaccination progress. Singapore’s earnings normalization is underway, and could be boosted by domestic re-opening. During GFC, PEs re-rated 91% from the bottom during the EPS normalization phase. Our new 12-month STI target 3,650 offers 18% upside. Top picks: AEM, AREIT, CD, CICT, DBS, ESR, FCT, OCBC, ST, UMS.

 

Read More ...



LionelLim8.16Check out our compilation of Target Prices




Share Prices

Counter NameLastChange
AEM Holdings4.180-0.070
Avarga0.285-0.010
Avi-Tech Electronics0.395-
BH Global0.260-
China Sunsine0.490-0.010
Food Empire0.760-0.010
Fortress Minerals0.365-0.025
Golden Energy0.290-0.015
GSS Energy0.073-0.004
InnoTek0.810-0.015
ISDN Holdings0.645-0.030
ISOTeam0.115-0.003
IX Biopharma0.225-
KSH Holdings0.350-
Leader Env0.079-
Medtecs Intl0.370-0.055
Moya Asia0.065-0.001
Nordic Group0.355-
Oxley Holdings0.200-0.010
Procurri0.305-
REX International0.189-0.010
Riverstone1.000-0.130
Roxy-Pacific0.4700.065
Southern Alliance Mining0.960-0.030
Sri Trang Agro1.340-0.050
Straco Corp.0.4750.005
Sunpower Group0.625-0.010
The Trendlines0.100-0.002
UG Healthcare0.345-0.060
Uni-Asia Group1.050-0.050
Wilmar Intl4.080-0.030
Yangzijiang Shipbldg1.440-0.040
Yinda Infocomm0.215-0.005

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 971 guests and no members online